Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Staring off wistfully into the middle distance, thinking, “Man, the mid-2010s were a time .” Whether or not you believe it ...